Research programme: neurodegenerative disorders therapeutics - Alnylam Pharmaceuticals/Medtronic

Drug Profile

Research programme: neurodegenerative disorders therapeutics - Alnylam Pharmaceuticals/Medtronic

Alternative Names: ALN-HTT; RNAi therapeutic drug-device combination for Huntington's disease - Alnylam/Medtronic; RNAi therapeutic programme - Alnylam Pharmaceuticals/Medtronic; RNAi therapeutics - Alnylam Pharmaceuticals/Medtronic

Latest Information Update: 16 Jul 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Alnylam Pharmaceuticals; Medtronic
  • Class
  • Mechanism of Action RNA interference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Huntington's disease; Neurodegenerative disorders

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in Huntington's-disease in USA (Intrastriatal, Infusion)
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Neurodegenerative-disorders in USA (Intrastriatal, Infusion)
  • 04 Nov 2010 Alnylam Pharmaceuticals, Medtronic and CHDI Foundation agree to collaborate on development of ALN HTT for Huntington's disease
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top